Advancing data-driven medicine: unlocking the potential of multimodal health data sets

Type:
Location:
Areas of Interest:

The potential of combining genomics with other health data modalities is massive. However, this influx of information presents a unique set of challenges that we are only beginning to tackle.

Over the past decade, we have witnessed a healthcare revolution catalyzed by next-generation sequencing. This shift has transformed our approach from a single-biomarker-driven analysis to a multi-biomarker-driven one. However, despite advancements in analytics, it is evident that healthcare providers often have no choice but to examine test results in isolation, making it challenging to uncover trends that emerge only when various data types are comprehensively visualized and analyzed.

Despite the immense potential of data integration, artificial intelligence (AI), and machine learning (ML), we are just scratching the surface of their capabilities. In this webinar, Dr. Menu will illustrate how SOPHiA GENETICS can propel data-driven medicine forward by leveraging the power of multimodal analytics. He will also delve into the significance of multimodality throughout the healthcare journey, using the ongoing multicentric clinical study, DEEP-Lung-IV (NCT04994795), focused on stage IV non-small cell lung cancer (NSCLC), as a practical exemplar.

Key takeaways:

Unlocking the potential of individualized data-driven medicine requires a transition from a statistical practice of medicine to a genuinely personalized one.
Achieving this transformation necessitates breaking down data silos across different instruments and institutions.
Building a global collective intelligence is vital for accelerating the widespread adoption of multimodal data analytics.

Agenda

Introduction to SOPHiA GENETICS
Why Multimodality?
Our Approach to Multimodality

Speaker

Philippe Menu, MD, PhD, MBA
Chief Medical Officer, SOPHiA GENETICS

Disclaimer: All rights reserved. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

Watch Webinar

Comments

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone(Required)

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services